Kornimate/medical-research-clean huggingface dataset:
oral and swallowing function in older adults

Conditions: Oropharyngeal Dysphagia

Summary: the purpose of this study is to learn about oral and swallowing function in older adults presenting to the emergency department. the hypothesis is that older adults often have problems with oral and swallowing function and these problems relate to other conditions. study activities are done during the emergency department visit and include providing saliva samples, completing a bedside water swallow test, completing oral function assessments, completing respiratory function tests, and answering survey questions.

oropharyngeal dysphagia is characterized by changes in swallow event timing, biomechanics, and pressure generation that occur with advancing age resulting in aspiration of bacteria-laden saliva, food, and liquid into the lungs. currently, oral and swallowing function is not routinely or comprehensively assessed in older adults despite poor oral health and oropharyngeal dysphagia being known risk factors for pneumonia, the leading infectious cause of mortality among adults 65+. this study seeks to extensively characterize oral and swallowing function in older adults presenting to the emergency department to clarify the relationship of oral hypofunction, dysphagia, and the upper airway microbiome. to achieve this aim, study procedures include a bedside dysphagia screen, oral health assessment, tongue pressure measurement, masticatory function assessment, respiratory function tests, salivary compositional analysis, oral microbiome analysis, and microphysiological system analysis which applies saliva samples to a bronchiolar lumen model to mimic aspiration and quantify cellular and tissue responses to the saliva microbiome and secreted mediators.

Eligibility criteria:
inclusion criteria: * age ≥ 60 * clinically stable and able (not npo) to safely drink water and eat a saltine cracker per ed provider exclusion criteria: * prisoner * non-english speaking
locoregional recurrence after neoadjuvant versus adjuvant chemotherapy

Conditions: Breast Cancer

Summary: neoadjuvant chemotherapy (nact) for early-stage breast cancer is associated with an increased risk of locoregional recurrence (lrr). however, few studies have conducted subgroup analyses of patients with various molecular subtypes, which are one of the determinant factors for treatments. the aim of the study is to investigate whether the risk of lrr after nact varies across tumor subtypes. the investigators retrospectively reviewed the medical records of female breast cancer patients who underwent breast-conserving surgery at three institutions between january 1, 2004, and dec 31, 2018.


Eligibility criteria:
inclusion criteria: * patients who underwent breast-conserving surgery for invasive breast cancer between 2004 and 2018 exclusion criteria: * total mastectomy * no pre- or postoperative chemotherapy * no radiation therapy * bilateral breast cancer * male breast cancer patients * secondary breast cancer * metachronous or synchronous cancers
me/cfs, hypermobility and craniocervical obstructions

Conditions: Chronic Fatigue Syndrome

Summary: a retrospective study on clinical and radiological findings in me/cfs


Eligibility criteria:
inclusion criteria: patients at a multidisciplinary specialist clinic accepting to participate exclusion criteria: none
gait perturbations to improve balance post-stroke

Conditions: Hemiparesis;Poststroke/CVA

Summary: individuals with stroke have balance and gait deficits. gait training does improve balance and gait abilities, but adding perturbations may have increase these effects. the objective was to compare the effect gait training with and without perturbations on balance and gait abilities in individuals with hemiparesis due to stroke at a chronic stage.


Eligibility criteria:
inclusion criteria: * able to walk at a comfortable speed less than 1.0 m/s * have reduced dynamic balance capacities (as evaluated by the mini-bestest; score below the 95% confidence interval of the mean score of the corresponding age group of normative data) * with or without a history of fall * be able to walk on a treadmill, without external support, such as handrails or walking aid, for at least 1 minute exclusion criteria: * hemineglect (more than 6 omissions on the bell cancellation test), * cognitive impairment (mini-mental state examination score under 24/30) * uncorrected visual deficit or pathologies other than stroke which can affect their gait or balance
efficacy study of topical neosh101 to treat male pattern hair loss

Conditions: Androgenetic Alopecia

Summary: the purpose of this study is to measure the hair growth response to topical neosh101 when applied twice daily to the balding scalp for 16 weeks. one hundred eighty men with norwood/hamilton grades iii-iv with thinning in the top and center of the scalp will participate. three equally sized treatment groups (60 men each) will receive either topical neosh101 2.0%, minoxidil 5%, or placebo.


Eligibility criteria:
inclusion criteria: * caucasian men, in general good health, aged 18-49 years * norwood/hamilton grades iii-iv, with thinning hair in the vertex area exclusion criteria: * concomitant dermatologic or medical condition(s) which may interfere with the investigator's ability to evaluate the subject's response to the study drug * treatment with a systemic or locally acting medication which may interfere with the study objectives, such as minoxidil treatment in the 6 months prior to study start, finasteride treatment in the 12 months prior to study start, or treatment with other investigational hair growth products in the 6 months prior to study start

Keywords: androgenetic alopecia male pattern hair loss male pattern baldness androgenetic alopecia or male pattern hair loss
trial on use of coloshield in transanal and anal surgery

Conditions: Fistula-in-ano; Rectal Polyp; Rectal Adenoma; Hemorrhoids; Anal Fissure

Summary: in various transanal and anal procedures it is desirable to clean the operating field from stool contamination. thus mechanical bowel preparation is not well tolerated by patients. enema does not provide sufficient effect. by the use of coloshield a rectal washout might be performed and enable a clean operating field. in this randomized controlled trial the macroscopic contamination of the rectum with and without coloshield is compared using the boston bowel preparation score (0-3).


Eligibility criteria:
inclusion criteria: * patients undergoing surgery for fistula-in-ano, transanal resection of rectal polyp or adenoma, haemorrhoids or anal fissure. exclusion criteria: * age \<18 years * inability to give informed consent * pregnancy * missing informed consent * emergency operation (\<24hours of diagnosis and admission at emergency room) * rectal strictures or stenosis * status post rectal resection or pelvic radiation therapy * inflammatory bowel disease with inclusion of the rectum * need for mechanical bowel preparation
itbs can increase frontal dopamine release in pet dopamine imaging.

Conditions: Schizophrenia

Summary: aim: 1. to confirm that patients with predominant negative symptoms in schizophrenia have deficits in frontal cortical dopamine release when compared with healthy control and patients with positive symptoms. 2. our previous study found patients with negative symptoms have more possibilities to have disorders in glucose metabolism, we wonder whether dopamine release, negative symptoms or glucose metabolism can be improved by itbs. study design: case control study.

eligibility criteria: predominant negative symptoms for positive and negative syndrome scale factor score for negative symptoms of 24 or more, and score of 4 or more on at least two of three core negative panss items, panss for positive symptoms of 19 or less, hamd depression scale of 16 or less. predominant positive symptoms for panss for positive symptoms of 20 or more. healthy control will be recruited matching the age and sex of patient groups, outcome measures: oral glucose tolerance test (ogtt), pet dopamine imaging.

Eligibility criteria:
inclusion criteria for negative group * diagnosed with schizophrenia according to icd-10 or dsm-v * positive and negative syndrome scale factor score for negative symptoms of 24 or moreand score of 4 or more on at least two of three core negative panss items * panss for positive symptoms of 19 or less, and hamd depression scale of 16 or less. * drug-naive inclusion criteria for positive group * panss for positive symptoms of 20 or more * drug-naive exclusion criteria: * drug or alcohol addiction * diagnosed with other major mental disorders according to icd-10 or dsm-v
autonomic regulation therapy in heart failure with preserved ejection fraction

Conditions: Congestive Heart Failure

Summary: the anthem-hfpef study is designed to demonstrate the safety and efficacy of vagus nerve stimulation (vns) with the cyberonics vns therapy system for the treatment of subjects with symptomatic heart failure with preserved and mid-range ejection fraction.

heart failure patients will be enrolled and implanted with a cervical vns system on the right side. after a 2-week post-implantation recovery period and a 10-week stimulation titration period, continuous periodic stimulation will be performed for 12 months, with data collection at 3, 6, 9, and 12 months.

Eligibility criteria:
inclusion criteria: patients with symptomatic heart failure, new york heart association (nyha) class ii/iii with preserved and mid-range ef (≥40%). exclusion criteria: -

Keywords: heart failure preserved ejection fraction vns vagus nerve autonomic regulation therapy
effect of community social mobilization for the prevention of hiv in young south african women

Conditions: Gender Relations

Summary: the overall purpose is to assess whether a community social mobilization (csm) program focused on young men ages 18-35 years of age changes gender norms in the community. the secondary purpose is to determine if there is a combined effect of csm and hptn 068 (conditional cash transfers) on hiv and hsv-2 incidence. the goal of the mobilization activities is to engage young men around the issues of gender norms, intimate partner violence and hiv risk and to encourage them to take action to protect young women and reduce hiv risk in their communities.


Eligibility criteria:
inclusion criteria: quantitative work * men and women ages 18-35 years * have lived in study area continuously for the past 12 months * able and willing to provide informed consent qualitative work * men and women ages 18-99 years * a community member, cat member or community mobilizer * able and willing to provide informed consent

Keywords: community mobilization hiv intimate partner violence gender norms
e7777 for the treatment of patients with peripheral t-cell lymphoma

Conditions: Peripheral T-Cell Lymphoma

Summary: the purpose of this phase 1 study is to determine the maximum tolerated dose (mtd) through observation of dose limiting toxicity (dlt), which is in advance defined, in patients with peripheral or cutaneous t-cell lymphoma.


Eligibility criteria:
lnclusion criteria: * male and female patients 20 to less than 80 years of age at the time of informed consent * patients histologically or cytologically diagnosed to have peripheral t -cell lymphoma * patients with a history of chemotherapy (including puva and retinoid) that resulted in relapse, recurrence and treatment resistance (just for the administration of e7777 alone) * patients subject to chop therapy and without a history of prior treatment with anthracycline or anthraquinone anticancer drugs (just for the administration of e7777 in combination with chop therapy) * eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1 * no carry-over of beneficial or adverse effects of the prior treatment that may affect the safety evaluation of the investigational drug (excluding grade 1 neuropathy and alopecia) exclusion criteria: * brain metastasis with clinical symptoms which requires treatment * serious systemic infection requiring intensive treatment * serious complications or histories * history of hypersensitivity to protein therapeutics * known to be positive for hiv antibody, hcv antibody, or hbs antigen * history of malignancy other than peripheral t-cell lymphoma and less than five years have elapsed since the last remission * patients who have undergone allogeneic hematopoietic stem cell transplantation * patients with a relapse within 6 months after autologous hematopoietic stem-cell transplantation

Keywords: neoplasms neoplasms by histologic type lymphoma non-hodgkin t- cell lymphatic diseases lymphoproliferative disorders lmmune system diseases lmmunoproliferative disorders
vascular and periodontal disease - microbial, genetic and histological causalities

Conditions: Periodontitis; Vascular Disease

Summary: the purpose of this study is to analyze genetic polymorphisms in genes encoding pro-inflammatory cytokines, and study the genetic predisposition to chronic periodontitis (cp) in combination with atherosclerotic cardiovascular (acd) and aneurysmal diseases. the investigators will also try to identify oral bacteria in atherosclerotic plaques and aneurysmal walls and thrombus. histological analyses of atherosclerotic plaques and aneurysmal wall will be performed.


Eligibility criteria:
inclusion criteria: * patients undergoing vascular surgery at oslo university hospital, aker, previously randomly collected patients with periodontitis, exclusion criteria: * patients whom undergone antibiotic treatment the past month. * patients whom undergone periodontal treatment the past 6 months. * patients with no teeth

Keywords: periodontitis vascular disease proinflammatory cytokines
clinical trial evaluating outcomes of self-fit and professionally fit hearing aids

Conditions: Hearing Loss

Summary: approximately 48 million people in the united states have hearing loss or hearing difficulties in noisy environments. whisper.ai inc has previously brought to market a commercial hearing aid system that reduces background noise and amplifies voices and sounds of interest using its proprietary platform based on machine learning and artificial intelligence technologies. whisper.ai inc now seeks to bring to market a new hearing system that will incorporate a "self-fitting" capability. self-fitting hearing aids have emerged in recent years as a potentially viable option to calibrate hearing aids to the needs of individual users without clinician intervention. the purpose of this project is to evaluate the efficiency and reliability of the fitting procedure and algorithms developed by whisper.ai inc. the study will be carried out using a randomized crossover design in two phases: in phase 1, subjects will be tested and a hearing aid will be fitted using conventional audiological standard procedures , and in phase 2, the subject will be tested and a hearing aid will be fitted using the results of the self-fitting algorithm. objective, subjective, and behavioral responses will be gathered from a variety of hearing-related surveys and tests, and will be analyzed quantitatively to evaluate the efficiency and reliability of the self-fitting algorithm. the investigators expect the fitting results of the whisper.ai self-fitting algorithm to be similar to those of standardized fitting procedures conducted by hearing professionals.


Eligibility criteria:
inclusion criteria: * adults age 18-80 years old * mild-to-moderate hearing loss in both ears from 500 to 4000 hz * reported one year of previous hearing aid experience in at least one ear * ability to use a laptop/desktop computer to browse the internet * ability to complete online surveys in a web browser * communicates verbally and in writing in english exclusion criteria: * history of neurological deficits (e.g. stroke, alzheimer's disease, etc.) * inability to remain alert throughout initial testing appointment

Keywords: self-fitting hearing aids conventional hearing aid fitting
examination of trends in colorectal cancer patients' clinical study experiences

Conditions: Colorectal Cancer

Summary: clinical study participation percentages haven't always been fully representative of a given demographic. participation in this observational clinical research is extremely valuable since it allows people with colorectal cancer to contribute their own experiences and unique viewpoints. these vital contributions have the potential to affect the development of novel therapies and support services dramatically. trial's findings will be critical in furthering the understanding of colorectal cancer, ultimately leading to better patient outcomes.


Eligibility criteria:
inclusion criteria: * participant has a diagnosis of colorectal cancer * patient has self-identified as planning to enroll in a clinical trial for colorectal cancer * patient is at least 18 years of age exclusion criteria: * inability to perform regular electronic reporting * any mental or medical condition that prevents the patient from giving informed consent or participating in the trial * pregnant or lactating woman

Keywords: colorectal cancer
nowdx test for the diagnosis of herpes simplex virus type 2

Conditions: HSV-2 Infection; Herpes Simplex Virus Infection

Summary: this study is designed to compare the performance of the nowdx hsv-2 test to a currently marketed device. the intent is to show the rapid test device is comparable to the currently marketed device. the nowdx hsv-2 test is intended for qualitatively detecting the presence or absence of human immunoglobulin g (igg) class antibodies to hsv-2 in human whole blood to aid in the diagnosis of infection caused by herpes simplex virus type 2 (hsv-2).

the objective of this study is to establish the performance characteristics of the nowdx hsv-2 test based on comparison to the herpeselect 1 and 2 immunoblot igg and herpeselect 2 elisa igg assays. the external clinical study along with in-house analytical studies will demonstrate the efficacy of the nowdx hsv-2 test as an aid in the diagnosis of hsv-2 infection for at home testing and point of care testing sites. participants will self test and be tested by clinical laboratory improvement amendments (clia) waived operators with the nowdx hsv-2 test at independent sites in florida, kentucky, and arizona. two sample types will be tested with the nowdx hsv-2 test for each participant: capillary whole blood and venous whole blood. sera from each participant will be tested at an independent reference laboratory. the nowdx hsv-2 test will be evaluated in diverse populations of sexually active persons who self-select for genital herpes testing, expectant mothers, and persons claiming to lack sexual experience.

Eligibility criteria:
* sexually active persons who self-select for syphilis testing n=750 participants; \~250 per study site inclusion criteria: sexually active persons 18-64 years old exclusion criteria: persons \ 64 years old; persons with limited or no reading skills; persons who previously participated in a nowdx study * expectant mothers n=90 participants; \~30 per study site inclusion criteria: expectant mothers ≥18 years old exclusion criteria: persons \<18 years old; persons with limited or no reading skills; persons who previously participated in a nowdx study * low prevalence population n=201 participants; \~67 per study site inclusion criteria: persons aged 18-64 years old claiming to lack sexual experience exclusion criteria: persons \ 64 years old; persons with limited or no reading skills; persons who previously participated in a nowdx study * lay users n=48 participants; \~16 per study site inclusion criteria: persons 18-64 years old; ½ high risk sexual behavior; ½ low risk sexual behavior exclusion criteria: persons \ 64 years old; persons with limited or no reading skills; persons who previously participated in a nowdx study

Keywords: hsv-2 genital herpes
prospective randomised study for use of chg dressing at entry site of evd's to reduce evd-associated infections

Conditions: Wound Contamination

Summary: the objective of this study is to assess the efficacy of 3m™ tegaderm™ chg i.v. securement dressing at the entry-site of a evd in reducing quantity of microorganisms (cfu/cm2) after a time period of 5 days as a surrogate marker for evd-associated infections \[1, 2\], compared to a nonantimicrobial polyurethane 3m tegaderm™ transparent film dressing. we aim to investigate, if the adjunct of an additional chg-impregnated device on a routinely basis for the daily care is as a valuable and effective option to reduce contamination of the evd entry-site and consecutive colonization of the catheter.

randomised, parallel group, single-centre phase iv trial comparing the change in the quantity of microorganisms (cfu/cm2) after a time period of 5 days (primary endpoint) as surrogate marker for evd-associated infections \[1, 2\], in patients undergoing evd with dressing at the entry site with 3m™ tegaderm™ chg i.v. securement dressing (study arm) versus 3m™ tegaderm™ i.v. advanced dressing (standard arm). secondary objectives are the comparison of regrowth (cfu/cm2) every 5th day before routine change of the device, cerebrospinal fluid (csf) cultures every 2nd day and sonication of the catheter tip after explantation (secondary endpoints). we hypothesize that bacterial contamination (cfu/cm2) of the evd entry-site after 5 days compared to baseline (bacterial regrowth since baseline) in subjects treated with the 3m™ tegaderm™ chg i.v. securement dressing is significantly lower compared to subjects treated with 3m™ tegaderm™ i.v. advanced dressing. quantitative microbiology of the catheter tip (sonication) might be reduced by this external intervention, as well as csf cultures. we will use an internal pilot study design \[3\]. the three step procedure includes: * initial sample size calculation * sample size review * final analysis.

Eligibility criteria:
inclusion criteria: - patients following the criteria cited below are included: patients undergoing implantation of an external ventricular drain (evd), frontal or occipital, due to a given underlying pathology. * written informed consent (ic) by patients and/or independent physician \[according 5.1\] * age ≥ 18 years exclusion criteria: * patients presenting one of the criteria cited below are excluded: * presence of clinical signs or laboratory findings suspicious infection * presence of antibiotic intake * traumatic brain injury (tbi) with evident or suspected dural breach (including skull base) * decision for rifampin impregnated ventricular catheter (bactiseal©) * known hypersensitivity to chlorhexidine (people from japanese origin) * age \< 18 years * participation in another study involving external ventricular drains * pregnancy or breastfeeding

Keywords: wound contamination